(0.02%) 5 333.00 points
(0.02%) 39 950 points
(-0.05%) 18 753 points
(-0.60%) $79.32
(-0.51%) $2.74
(-0.87%) $2 417.20
(-2.47%) $31.63
(-1.83%) $1 044.20
(0.02%) $0.921
(0.19%) $10.72
(-0.03%) $0.787
(0.02%) $90.69
10.52% $ 0.308
Live Chart Being Loaded With Signals
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...
Stats | |
---|---|
Tagesvolumen | 24 323.00 |
Durchschnittsvolumen | 190 072 |
Marktkapitalisierung | 3.42M |
EPS | $0 ( 2024-05-20 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00900 (2.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2021-05-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-05-01 | Tauzin W J | Buy | 8 000 | Stock Option right to buy) |
2022-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-01-01 | Tauzin W J | Buy | 4 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.83 |
Last 100 transactions |
Buy: 44 704 561 | Sell: 8 187 803 |
Avalon GloboCare Corp. Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Avalon GloboCare Corp. Finanzdaten
Annual | 2023 |
Umsatz: | $1.26M |
Bruttogewinn: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2023 |
Umsatz: | $1.26M |
Bruttogewinn: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2022 |
Umsatz: | $1.20M |
Bruttogewinn: | $272 728 (22.69 %) |
EPS: | $-1.360 |
FY | 2021 |
Umsatz: | $1.39M |
Bruttogewinn: | $414 518 (29.80 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.